ArticleFuture oncology (London, England)2025
Tumor budding and Ki-67 proliferation index as biomarkers for NAC response and prognosis in breast cancer.
Article in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Defining the optimal Ki67 cutoff values for survival prediction in neoadjuvant chemotherapy-treated patients with breast cancer.Frontiers in surgery · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsNeoadjuvant chemotherapy (NAC) enhances the possibility of breast conserving surgery and improves survival in patients with complete response in breast carcinoma. The most crucial step for maximum benefit and minimum damage in neoadjuvant chemotherapy is selecting the most eligible patient. MATERIALS &
methodsThe study included 191 patients diagnosed with invasive breast carcinoma of no special type in needle biopsy samples. The effect of tumor budding (TB) and the Ki-67 proliferation index on NAC response and survival were assessed.
resultsTumor budding was associated with metastasis (p < 0.001), survival (p = 0.002), and molecular subtype (p = 0.045). In multivariate analysis, TB was an independent risk factor for disease free survival (DFS). There was no significant correlation between NAC response and TB (p = 0.104). The cutoff value of the Ki-67 proliferation index in response to NAC was determined as 19%.
conclusionNeoadjuvant chemotherapy response is observed more positively in tumors with KI-67 index of 19% and above. Although intratumoral TB is not detected in correlation with NAC response, it has an independent effect on DFS. Adding TB parameter to the pathology report format of needle biopsy materials has the potential to make a positive contribution to patient management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.